Taken together, HDAC inhibitors, such as trichostatin A, vorinostat, and valproic acid, may be exploited to be potential chemopreventive treatment for prevention of HCC development for cirrhosis patients. This evidence concerns the gene HDAC9 and Cirrhosis.